These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21330910)

  • 1. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.
    Tudor D; Bomsel M
    AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
    Franquelim HG; Chiantia S; Veiga AS; Santos NC; Schwille P; Castanho MA
    AIDS; 2011 Feb; 25(4):419-28. PubMed ID: 21245727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41.
    Duchemin M; Tudor D; Cottignies-Calamarte A; Bomsel M
    Front Immunol; 2020; 11():1141. PubMed ID: 32582208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
    Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
    J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.
    Alam SM; Liao HX; Dennison SM; Jaeger F; Parks R; Anasti K; Foulger A; Donathan M; Lucas J; Verkoczy L; Nicely N; Tomaras GD; Kelsoe G; Chen B; Kepler TB; Haynes BF
    J Virol; 2011 Nov; 85(22):11725-31. PubMed ID: 21917975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
    Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
    Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
    Perez LG; Costa MR; Todd CA; Haynes BF; Montefiori DC
    J Virol; 2009 Aug; 83(15):7397-410. PubMed ID: 19458010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
    Bomsel M; Tudor D; Drillet AS; Alfsen A; Ganor Y; Roger MG; Mouz N; Amacker M; Chalifour A; Diomede L; Devillier G; Cong Z; Wei Q; Gao H; Qin C; Yang GB; Zurbriggen R; Lopalco L; Fleury S
    Immunity; 2011 Feb; 34(2):269-80. PubMed ID: 21315623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection.
    Koup RA; Pikora CA; Mazzara G; Panicali D; Sullivan JL
    Viral Immunol; 1991; 4(4):215-23. PubMed ID: 1726398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.
    Guenaga J; Dosenovic P; Ofek G; Baker D; Schief WR; Kwong PD; Karlsson Hedestam GB; Wyatt RT
    PLoS One; 2011 Jan; 6(1):e16074. PubMed ID: 21297864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
    Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.
    Perez LG; Zolla-Pazner S; Montefiori DC
    J Virol; 2013 May; 87(9):5287-90. PubMed ID: 23408628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.
    Smith SA; Derdeyn CA
    J Virol; 2017 May; 91(9):. PubMed ID: 28250119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
    Huarte N; Lorizate M; Kunert R; Nieva JL
    FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.